Quick Comparison
| Bacopa Monnieri | PEA (Palmitoylethanolamide) | |
|---|---|---|
| Half-Life | 2-6 hours (bacosides) | 1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability |
| Typical Dosage | Standard: 300-600 mg daily of extract standardized to 50% bacosides (e.g., Bacognize or Synapsa). Take with fat for absorption. Allow 8-12 weeks for full effects. Evening dosing preferred due to mild sedation. | Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks. |
| Administration | Oral (capsules, powder). Fat-soluble — take with a meal containing fat. | Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability. |
| Research Papers | 8 papers | 10 papers |
| Categories |
Mechanism of Action
Bacopa Monnieri
Bacopa's bacosides (bacosides A and B, bacopaside I-VII) enhance synaptic communication by increasing dendritic branching, spine density, and synaptic activity in the hippocampus via modulation of neural cell adhesion molecules (NCAM) and FGF-2. They modulate serotonin through 5-HT3 receptor antagonism (reducing anxiety) and 5-HT2A modulation, dopamine through D1/D2 receptor modulation, and acetylcholine through enhancement of choline acetyltransferase. Bacosides upregulate tryptophan hydroxylase (TPH) and serotonin transporter (SERT) expression, increasing serotonin synthesis and reuptake. The antioxidant properties of bacosides reduce lipid peroxidation and protein carbonylation in the hippocampus via free radical scavenging, protecting neurons from oxidative damage during memory formation. They may enhance CREB phosphorylation and BDNF expression.
PEA (Palmitoylethanolamide)
PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.
Risks & Safety
Bacopa Monnieri
Common
Gastrointestinal discomfort (cramping, nausea, bloating), fatigue, dry mouth.
Serious
May interact with thyroid medications.
Rare
Increased bowel movements, decreased appetite.
PEA (Palmitoylethanolamide)
Common
Very well-tolerated — rare side effects. Mild GI discomfort.
Serious
None documented. Over 30 clinical trials confirm excellent safety profile.
Rare
Skin rash.
Full Profiles
Bacopa Monnieri →
An Ayurvedic herb used for thousands of years as a memory enhancer. Modern research confirms it — Bacopa reliably improves memory formation, recall speed, and information retention. The catch is that benefits require 8-12 weeks of daily use to manifest; it is not an acute cognitive enhancer. The bacosides (active compounds) are also mildly sedating, making evening dosing common.
PEA (Palmitoylethanolamide) →
An endogenous fatty acid amide produced naturally in the body in response to pain and inflammation. PEA activates PPAR-alpha receptors and indirectly enhances endocannabinoid signaling without binding to cannabinoid receptors. It has strong evidence for neuropathic pain, neuroinflammation, and neuroprotection. Unlike anti-inflammatory drugs, it resolves inflammation rather than merely suppressing it.